Thermo Fisher Scientific reported third-quarter adjusted earnings of $6.68 per share on Wednesday, exceeding the $6.40 analyst estimate. Quarterly sales increased 9% from a year earlier to $12,137 million, surpassing the $11,946 million consensus estimate. Organic revenue grew 6%. The adjusted operating margin reached 24.5%, compared with 23.3% a year earlier.
Thermo Fisher raised fiscal 2026 adjusted earnings guidance from between $24.93 and $25.33 per share to between $25.13 and $25.43 per share. The consensus earnings estimate was $25.14 per share. Thermo Fisher increased 2026 sales guidance from between $47.4 billion and $48.10 billion to between $47.70 billion and $48.20 billion. The comparative sales estimate was $47,885 million. Thermo Fisher said during the earnings call that better end-market conditions seen in the second quarter persisted into the third quarter, with strong customer activity.
Life Sciences Solutions reported third-quarter revenue of $2,719 million, up 5% from the prior-year quarter. Organic revenue in Life Sciences Solutions grew 1%. The bioproduction business contributed the most to the segment's growth. Analytical Instruments reported quarterly revenue of $2.00 billion, up 6%. Organic revenue in Analytical Instruments also grew 6%. Electron microscopy contributed the most to the segment's growth, while chromatography and mass spectrometry also performed well.
Specialty Diagnostics reported third-quarter revenue of $1,098 million, down 6% from a year earlier. Organic revenue in Specialty Diagnostics remained unchanged. Transplant diagnostics contributed the most to growth within the segment. Laboratory Products and Biopharma Services reported quarterly revenue of $6,863 million, up 15%. Organic revenue in Laboratory Products and Biopharma Services grew 10%. Thermo Fisher said pharma services, the research and safety market channel, and clinical research each delivered strong third-quarter growth.
Chairman and CEO Marc Casper said the pharma and biotech business achieved high-single-digit growth during the quarter. Casper said pharma services and the research and safety market channel contributed the most to that growth. Academic and government revenue remained unchanged during the quarter. Chromatography and mass spectrometry performed well in the academic and government market.
Thermo Fisher shares traded 1.04% higher at $694.55 at publication on Wednesday. Benzinga Pro data showed the shares trading near the 52-week high of $704.00.
Thermo Fisher Scientific Q3 Earnings Exceed Estimates, Shares Rise
BenzingaShare
Summary
Thermo Fisher Scientific (NYSE:TMO) reported Q3 adjusted earnings of $6.68 per share, beating the consensus mechanism estimate of $6.40. Quarterly sales rose 9% to $12,137 million, above the $11,946 million consensus. The firm raised 2026 guidance for both earnings and sales. Shares climbed 1.04% to $694.55. The results reflect strong operational performance and align with a Nakamoto consensus-like alignment of expectations and outcomes.
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.